TY - JOUR
T1 - The utility of traditional Chinese medicine (Shenmai) in the cardiac rehabilitation after coronary artery bypass grafting
T2 - A single-center randomized clinical trial
AU - Zhang, Chunxiao
AU - Zheng, Yaguang
AU - Chen, Tao
AU - Wang, Shengyu
AU - Xu, Meng
N1 - Funding Information:
This study is supported by Beijing Municipal Administration of Hospitals Incubating Program ,Code: PZ2019006; the Foundation of Beijing Anzhen Hospital, Capital Medical University (No. 2013Z04, No. 2016P020).
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/12
Y1 - 2019/12
N2 - Objective: examine the efficacy and safety of Shenmai to the cardiac rehabilitation in patients received coronary artery bypass grafting. Design: a single-center randomized, single blind clinical trial. Setting: Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Subjects: Patients with coronary artery disease who received coronary artery bypass grafting in our center were studied. They must be competent to complete the 6-minute walking test without any assistance and without any severe comorbidity. Interventions: in Shemmai group, the participants were treated with Shenmai injection (100 ml/day) right after the surgery to discharge for 9.28 ± 3.75 days and then capsule (3.6 g/day) sequentially for 30 days in addition to the cardiac rehabilitation. In control group, only cardiac rehabilitation was conducted. Main measures: the 6-Minute Walking Test was measured at three time points: one day before operation, on the day of discharge and 30 days follow up. Results: The sample (n = 166) was predominately male (84%), with mean age was 61.12 ± 9.13 years. There was no significant difference between groups in baseline characteristics and the procedural characteristics. There was one death in control group and one stroke in Shenmai group right after the surgery. Overall, there was group (p =.005) and time effect (p <.001) on the 6-minute walking distance. Participants in the Shenmai group walked longer distance in meters compared with control group on the day of discharge (314.54 ± 64.14 vs. 271.29 ± 76.82, P <.001), while no significant differences before operation (399.72 ± 93.19 vs. 403.67 ± 91.99, p =.78) and on 30-day follow up (436.54 ± 67.64 vs. 421.64 ± 83.53, p =.21). Conclusion: Shenmai improves the exercise tolerance in the early stage of the cardiac rehabilitation for patients received coronary artery bypass grafting.
AB - Objective: examine the efficacy and safety of Shenmai to the cardiac rehabilitation in patients received coronary artery bypass grafting. Design: a single-center randomized, single blind clinical trial. Setting: Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Subjects: Patients with coronary artery disease who received coronary artery bypass grafting in our center were studied. They must be competent to complete the 6-minute walking test without any assistance and without any severe comorbidity. Interventions: in Shemmai group, the participants were treated with Shenmai injection (100 ml/day) right after the surgery to discharge for 9.28 ± 3.75 days and then capsule (3.6 g/day) sequentially for 30 days in addition to the cardiac rehabilitation. In control group, only cardiac rehabilitation was conducted. Main measures: the 6-Minute Walking Test was measured at three time points: one day before operation, on the day of discharge and 30 days follow up. Results: The sample (n = 166) was predominately male (84%), with mean age was 61.12 ± 9.13 years. There was no significant difference between groups in baseline characteristics and the procedural characteristics. There was one death in control group and one stroke in Shenmai group right after the surgery. Overall, there was group (p =.005) and time effect (p <.001) on the 6-minute walking distance. Participants in the Shenmai group walked longer distance in meters compared with control group on the day of discharge (314.54 ± 64.14 vs. 271.29 ± 76.82, P <.001), while no significant differences before operation (399.72 ± 93.19 vs. 403.67 ± 91.99, p =.78) and on 30-day follow up (436.54 ± 67.64 vs. 421.64 ± 83.53, p =.21). Conclusion: Shenmai improves the exercise tolerance in the early stage of the cardiac rehabilitation for patients received coronary artery bypass grafting.
KW - 6-minute walking test
KW - Cardiac rehabilitation
KW - Coronary artery bypass grafting
KW - Randomized clinical trial
KW - Shenmai
KW - Cardiac Rehabilitation/methods
KW - Single-Blind Method
KW - Drugs, Chinese Herbal/therapeutic use
KW - Medicine, Chinese Traditional
KW - Coronary Artery Disease/drug therapy
KW - Humans
KW - Middle Aged
KW - Male
KW - Combined Modality Therapy
KW - Exercise Test
KW - Exercise Tolerance
KW - Coronary Artery Bypass
KW - Female
KW - Aged
KW - Drug Combinations
UR - http://www.scopus.com/inward/record.url?scp=85074013542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074013542&partnerID=8YFLogxK
U2 - 10.1016/j.ctim.2019.102203
DO - 10.1016/j.ctim.2019.102203
M3 - Article
C2 - 31779994
AN - SCOPUS:85074013542
SN - 0965-2299
VL - 47
JO - Complementary Therapies in Medicine
JF - Complementary Therapies in Medicine
M1 - 102203
ER -